In contrast, the data on medication and severe COVID-19 in IBD patients using the SECURE-IBD registry including 1,439 patients found that a combination therapy of anti-TNF and thiopurines may be associated with an increased risk of COVID-19 adverse outcomes compared with anti-TNF or thiopurine monotherapy [adjusted OR: 4.08, 95% CI: 1.73–9.61] [16]. The gene discussed is TNF; the disease is inflammatory bowel disease.